Andrew R Branagan

32PUBLICATIONS
81CO-AUTHORS
Molecular targetsHaematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Tumour immunologyAutoimmunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (32)

|Jul 08, 2026
WNK2 oncogenicity revealed by the discovery and functional characterization of novel gene isoforms in MYD88 mutated Waldenström's Macroglobulinemia.

|Apr 22, 2026
Validation and refinement of the new Consensus Genomic Staging (CGS) of high-risk multiple myeloma (HRMM) in relapsed and refractory patients treated with BCMA CAR-T.

|Mar 15, 2026
Final Report of a Phase II Study of Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia.

Jorge J Castillo, Andrew R Branagan, Alberto Guijosa

|Feb 11, 2026
Evolution of tumor subclones and T-cell dynamics underlie variable ibrutinib responses in Waldenström macroglobulinemia.

Hao Sun, Romanos Sklavenitis Pistofidis, Shirong Liu

|Jan 27, 2026
Ruxolitinib for ciltacabtagene autoleucel-associated refractory diarrhea.

Viktoria Blumenberg, Filippo Birocchi, Angela Shih

|Jan 22, 2026
Clinicopathological features and management of IgM multiple myeloma and Waldenstrom macroglobulinemia.

Shayna Sarosiek, Jorge J Castillo, Zachary R Hunter

Pageof 6

Frequent Collaborators

21 joint publications

Jorge J Castillo

21 joint publications

Steven P Treon

17 joint publications

Zachary R Hunter

11 joint publications

Shayna Sarosiek